Virus plus immunotherapy combo targets hard-to-treat neuroendocrine cancers
Disease control
Recruiting now
This early-phase trial tests a virus that attacks cancer cells (SVV-001) together with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced neuroendocrine tumors or carcinomas that have worsened after standard treatment. The main goals are to find the safest…
Phase: PHASE1 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated May 26, 2026 10:06 UTC